Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M. Dreyling; M. Ghielmini; S. Rule; G. Salles; Marco LADETTO; S. H. Tonino; K. Herfarth; J. F. Seymour; M. Jerkeman

doi:10.1016/j.annonc.2020.11.008

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M. Dreyling, M. Ghielmini, S. Rule, G. Salles, Marco LADETTO, S. H. Tonino, K. Herfarth, J. F. Seymour, M. Jerkeman

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Lingua originale	Inglese
pagine (da-a)	298-308
Numero di pagine	11
Rivista	Annals of Oncology
Volume	32
Numero di pubblicazione	3
DOI	https://doi.org/10.1016/j.annonc.2020.11.008
Stato di pubblicazione	Pubblicato - 2021

Keywords

Antineoplastic Combined Chemotherapy Protocols
Follow-Up Studies
Health Planning Guidelines
Humans
Lymphoma, Follicular
Neoplasm Recurrence, Local
Neoplasm Staging
Rituximab
antibody
chemotherapy
follicular lymphoma
lenalidomide
radiotherapy

Accesso al documento

10.1016/j.annonc.2020.11.008

https://hdl.handle.net/11579/145799

Altri file e collegamenti

handle

Cita questo

@article{0b37a86b5ddc4352ba1d890ae87557ba,

title = "Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",

keywords = "Antineoplastic Combined Chemotherapy Protocols, Follow-Up Studies, Health Planning Guidelines, Humans, Lymphoma, Follicular, Neoplasm Recurrence, Local, Neoplasm Staging, Rituximab, antibody, chemotherapy, follicular lymphoma, lenalidomide, radiotherapy, Antineoplastic Combined Chemotherapy Protocols, Follow-Up Studies, Health Planning Guidelines, Humans, Lymphoma, Follicular, Neoplasm Recurrence, Local, Neoplasm Staging, Rituximab, antibody, chemotherapy, follicular lymphoma, lenalidomide, radiotherapy",

author = "M. Dreyling and M. Ghielmini and S. Rule and G. Salles and Marco LADETTO and Tonino, {S. H.} and K. Herfarth and Seymour, {J. F.} and M. Jerkeman",

note = "Funding Information: MD has reported scientific advisory boards for Accerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche and Sandoz, speaker's honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research support from Celgene, Janssen, Mundipharma and Roche; GS has reported advisory boards or consulting for AbbVie, Autolus, Celgene, Genmab, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, MorphoSys, Novartis, Roche, Servier and Takeda and educational events with AbbVie, Amgen, Celgene, Gilead, Janssen, Kite, MorphoSys, Novartis, Roche, Servier and Takeda; ML has reported consultancy, advisory boards, scientific meetings, institutional research support and contracts from AbbVie, Acerta, Amgen, Archigen, ADC Therapeutics, BeiGene, Celgene, Gilead, J&J, Jazz, Roche, Sandoz and Takeda and has received research grants from Celgene, J&J and BeiGene; KH has received research support from Roche; JFS has reported advisory boards for AbbVie, Celgene, Janssen, Roche, Acerta, Genentech, Gilead, Mei Pharma, MorphoSys, Sunesis and Takeda, speaker's bureau for AbbVie, Celgene and Roche and has received research funding from AbbVie, Celgene, Roche and Janssen; MJ has received research funding from Celgene, Roche, Gilead, AbbVie and Janssen and honoraria from Kite, Kyowa-Kirin and Acerta; MG , SR and SHT have declared no conflicts of interest. Funding Information: The ESMO Guidelines Committee thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. They also thank the European Cancer Patient Coalition and the following patient organisation for their review: the Polish Lymphoma Association Owl Eyes. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. MD has reported scientific advisory boards for Accerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche and Sandoz, speaker's honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research support from Celgene, Janssen, Mundipharma and Roche; GS has reported advisory boards or consulting for AbbVie, Autolus, Celgene, Genmab, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, MorphoSys, Novartis, Roche, Servier and Takeda and educational events with AbbVie, Amgen, Celgene, Gilead, Janssen, Kite, MorphoSys, Novartis, Roche, Servier and Takeda; ML has reported consultancy, advisory boards, scientific meetings, institutional research support and contracts from AbbVie, Acerta, Amgen, Archigen, ADC Therapeutics, BeiGene, Celgene, Gilead, J&J, Jazz, Roche, Sandoz and Takeda and has received research grants from Celgene, J&J and BeiGene; KH has received research support from Roche; JFS has reported advisory boards for AbbVie, Celgene, Janssen, Roche, Acerta, Genentech, Gilead, Mei Pharma, MorphoSys, Sunesis and Takeda, speaker's bureau for AbbVie, Celgene and Roche and has received research funding from AbbVie, Celgene, Roche and Janssen; MJ has received research funding from Celgene, Roche, Gilead, AbbVie and Janssen and honoraria from Kite, Kyowa-Kirin and Acerta; MG, SR and SHT have declared no conflicts of interest.",

year = "2021",

doi = "10.1016/j.annonc.2020.11.008",

language = "English",

volume = "32",

pages = "298--308",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

AU - Dreyling, M.

AU - Ghielmini, M.

AU - Rule, S.

AU - Salles, G.

AU - LADETTO, Marco

AU - Tonino, S. H.

AU - Herfarth, K.

AU - Seymour, J. F.

AU - Jerkeman, M.

N1 - Funding Information: MD has reported scientific advisory boards for Accerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche and Sandoz, speaker's honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research support from Celgene, Janssen, Mundipharma and Roche; GS has reported advisory boards or consulting for AbbVie, Autolus, Celgene, Genmab, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, MorphoSys, Novartis, Roche, Servier and Takeda and educational events with AbbVie, Amgen, Celgene, Gilead, Janssen, Kite, MorphoSys, Novartis, Roche, Servier and Takeda; ML has reported consultancy, advisory boards, scientific meetings, institutional research support and contracts from AbbVie, Acerta, Amgen, Archigen, ADC Therapeutics, BeiGene, Celgene, Gilead, J&J, Jazz, Roche, Sandoz and Takeda and has received research grants from Celgene, J&J and BeiGene; KH has received research support from Roche; JFS has reported advisory boards for AbbVie, Celgene, Janssen, Roche, Acerta, Genentech, Gilead, Mei Pharma, MorphoSys, Sunesis and Takeda, speaker's bureau for AbbVie, Celgene and Roche and has received research funding from AbbVie, Celgene, Roche and Janssen; MJ has received research funding from Celgene, Roche, Gilead, AbbVie and Janssen and honoraria from Kite, Kyowa-Kirin and Acerta; MG , SR and SHT have declared no conflicts of interest. Funding Information: The ESMO Guidelines Committee thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. They also thank the European Cancer Patient Coalition and the following patient organisation for their review: the Polish Lymphoma Association Owl Eyes. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. MD has reported scientific advisory boards for Accerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche and Sandoz, speaker's honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research support from Celgene, Janssen, Mundipharma and Roche; GS has reported advisory boards or consulting for AbbVie, Autolus, Celgene, Genmab, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, MorphoSys, Novartis, Roche, Servier and Takeda and educational events with AbbVie, Amgen, Celgene, Gilead, Janssen, Kite, MorphoSys, Novartis, Roche, Servier and Takeda; ML has reported consultancy, advisory boards, scientific meetings, institutional research support and contracts from AbbVie, Acerta, Amgen, Archigen, ADC Therapeutics, BeiGene, Celgene, Gilead, J&J, Jazz, Roche, Sandoz and Takeda and has received research grants from Celgene, J&J and BeiGene; KH has received research support from Roche; JFS has reported advisory boards for AbbVie, Celgene, Janssen, Roche, Acerta, Genentech, Gilead, Mei Pharma, MorphoSys, Sunesis and Takeda, speaker's bureau for AbbVie, Celgene and Roche and has received research funding from AbbVie, Celgene, Roche and Janssen; MJ has received research funding from Celgene, Roche, Gilead, AbbVie and Janssen and honoraria from Kite, Kyowa-Kirin and Acerta; MG, SR and SHT have declared no conflicts of interest.

PY - 2021

Y1 - 2021

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Follow-Up Studies

KW - Health Planning Guidelines

KW - Humans

KW - Lymphoma, Follicular

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Rituximab

KW - antibody

KW - chemotherapy

KW - follicular lymphoma

KW - lenalidomide

KW - radiotherapy

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Follow-Up Studies

KW - Health Planning Guidelines

KW - Humans

KW - Lymphoma, Follicular

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Rituximab

KW - antibody

KW - chemotherapy

KW - follicular lymphoma

KW - lenalidomide

KW - radiotherapy

UR - https://iris.uniupo.it/handle/11579/145799

U2 - 10.1016/j.annonc.2020.11.008

DO - 10.1016/j.annonc.2020.11.008

M3 - Article

SN - 0923-7534

VL - 32

SP - 298

EP - 308

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -